Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15650148 | 1.00 | HSD11B1 (0.54) | HSD11B1LRRK2LMNAHTR4ALDH1A1 | |
| SCHEMBL15653410 | 1.00 | HSD11B1 (0.54) | HSD11B1LRRK2LMNAHTR4ALDH1A1 | |
| SCHEMBL15651498 | 0.92 | HSD11B1 (0.59) | HSD11B1LRRK2LMNAHTR4ALDH1A1 | |
| SCHEMBL15652121 | 0.91 | HSD11B1 (0.49) | HSD11B1LMNAHTR4ALDH1A1CHRM4 | |
| SCHEMBL29531684 | 0.90 | HSD11B1 (0.54) | HSD11B1LMNAHTR4 | |
| SCHEMBL15651433 | 0.87 | HSD11B1 (0.54) | HSD11B1LRRK2LMNAHTR4ALDH1A1 | |
| SCHEMBL14068213 | 0.87 | HSD11B1 (0.54) | HSD11B1LRRK2LMNAHTR4ALDH1A1 | |
| SCHEMBL15650487 | 0.87 | HSD11B1 (0.54) | HSD11B1LRRK2LMNAHTR4ALDH1A1 | |
| SCHEMBL13575562 | 0.87 | HSD11B1 (0.59) | HSD11B1LMNAHTR4ALDH1A1CHRM4 | |
| SCHEMBL29530995 | 0.87 | HSD11B1 (0.59) | HSD11B1LMNAHTR4ALDH1A1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-2010542-B1 | 4,5-DIHYDRO-[1,2,4]TRIAZOLO[4,3-F]PTERIDINES AS PLK1 PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2011038185-A2 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2007120752-A2 | 4, 5-DIHYDRO- [1, 2, 4] TRIAZOLO [4, 3-F] PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HSD11B1 3408/4885LRRK2 1/4885LMNA 3015/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HSD11B1 4122/4885LRRK2 1/4885LMNA 3243/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HSD11B1 3408/4885LRRK2 1/4885LMNA 3015/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HSD11B1 3523/4885LRRK2 1/4885LMNA 3115/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HSD11B1 3523/4885LRRK2 1/4885LMNA 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.